Neuro-oncology advances最新文献

{"title":"Vorasidenib in IDH mutant WHO grade 2 gliomas: time to stop sitting on the fence?","authors":"Angelo Dipasquale, Enrico Franceschi, Giuseppe Lombardi, Matteo Simonelli","doi":"10.1093/noajnl/vdae003","DOIUrl":"10.1093/noajnl/vdae003","url":null,"abstract":"","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"6 1","pages":"vdae003"},"PeriodicalIF":0.0,"publicationDate":"2024-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10838118/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139682232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular prognostication in grade 3 meningiomas and p16/MTAP immunohistochemistry for predicting <i>CDKN2A/B</i> status.","authors":"Kira Tosefsky, Karina Chornenka Martin, Alexander D Rebchuk, Justin Z Wang, Farshad Nassiri, Amy Lum, Gelareh Zadeh, Serge Makarenko, Stephen Yip","doi":"10.1093/noajnl/vdae002","DOIUrl":"10.1093/noajnl/vdae002","url":null,"abstract":"<p><strong>Background: </strong>The World Health Organization 2021 classification introduces molecular grading criteria for anaplastic meningiomas, including <i>TERT</i> promoter (<i>TERTp</i>) mutations and <i>CDKN2A/B</i> homozygous deletion. Additional adverse prognostic factors include H3K27me3 and BAP1 loss. The aim of this study was to explore whether these molecular alterations stratified clinical outcomes in a single-center cohort of grade 3 meningiomas. Additionally, we examined whether p16 and MTAP immunohistochemistry can predict <i>CDKN2A/B</i> status.</p><p><strong>Methods: </strong>Clinical and histopathological information was obtained from the electronic medical records of grade 3 meningiomas resected at a tertiary center between 2007 and 2020. Molecular testing for <i>TERTp</i> mutations and <i>CDKN2A/B</i> copy-number status, methylation profiling, and immunohistochemistry for H3K27me3, BAP1, p16, and methylthioadenosine phosphorylase (MTAP) were performed. Predictors of survival were identified by Cox regression.</p><p><strong>Results: </strong>Eight of 15 cases demonstrated elevated mitotic index (≥20 mitoses per 10 consecutive high-power fields), 1 tumor exhibited BAP1 loss, 4 harbored <i>TERTp</i> mutations, and 3 demonstrated <i>CDKN2A/B</i> homozygous deletion. Meningiomas with <i>TERTp</i> mutations and/or <i>CDKN2A/B</i> homozygous deletion showed significantly reduced survival compared to anaplastic meningiomas with elevated mitotic index alone. Immunohistochemical loss of p16 and MTAP demonstrated high sensitivity (67% and 100%, respectively) and specificity (100% and 100%, respectively) for predicting <i>CDKN2A/B</i> status.</p><p><strong>Conclusions: </strong>Molecular alterations of grade 3 meningiomas stratify clinical outcomes more so than histologic features alone. Immunohistochemical loss of p16 and MTAP show promise in predicting <i>CDKN2A/B</i> status.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"6 1","pages":"vdae002"},"PeriodicalIF":3.7,"publicationDate":"2024-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10824160/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139577166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor Treating Fields (TTFields) for Spinal Metastasis - the Case for Bone Removal and Spinal Implants as Waveguides to Enhance Field Strength at the Target","authors":"C. Tatsui, Kristen W Carlson, Chirag B. Patel","doi":"10.1093/noajnl/vdad170","DOIUrl":"https://doi.org/10.1093/noajnl/vdad170","url":null,"abstract":"","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"1 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139389511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toward image-based personalization of glioblastoma therapy: A clinical and biological validation study of a novel, deep learning-driven tumor growth model.","authors":"Marie-Christin Metz, Ivan Ezhov, Jan C Peeken, Josef A Buchner, Jana Lipkova, Florian Kofler, Diana Waldmannstetter, Claire Delbridge, Christian Diehl, Denise Bernhardt, Friederike Schmidt-Graf, Jens Gempt, Stephanie E Combs, Claus Zimmer, Bjoern Menze, Benedikt Wiestler","doi":"10.1093/noajnl/vdad171","DOIUrl":"10.1093/noajnl/vdad171","url":null,"abstract":"<p><strong>Background: </strong>The diffuse growth pattern of glioblastoma is one of the main challenges for accurate treatment. Computational tumor growth modeling has emerged as a promising tool to guide personalized therapy. Here, we performed clinical and biological validation of a novel growth model, aiming to close the gap between the experimental state and clinical implementation.</p><p><strong>Methods: </strong>One hundred and twenty-four patients from The Cancer Genome Archive (TCGA) and 397 patients from the UCSF Glioma Dataset were assessed for significant correlations between clinical data, genetic pathway activation maps (generated with PARADIGM; TCGA only), and infiltration (<i>D</i>_w) as well as proliferation (ρ) parameters stemming from a Fisher-Kolmogorov growth model. To further evaluate clinical potential, we performed the same growth modeling on preoperative magnetic resonance imaging data from 30 patients of our institution and compared model-derived tumor volume and recurrence coverage with standard radiotherapy plans.</p><p><strong>Results: </strong>The parameter ratio <i>D</i>_w/ρ (<i>P</i> < .05 in TCGA) as well as the simulated tumor volume (<i>P</i> < .05 in TCGA/UCSF) were significantly inversely correlated with overall survival. Interestingly, we found a significant correlation between 11 proliferation pathways and the estimated proliferation parameter. Depending on the cutoff value for tumor cell density, we observed a significant improvement in recurrence coverage without significantly increased radiation volume utilizing model-derived target volumes instead of standard radiation plans.</p><p><strong>Conclusions: </strong>Identifying a significant correlation between computed growth parameters and clinical and biological data, we highlight the potential of tumor growth modeling for individualized therapy of glioblastoma. This might improve the accuracy of radiation planning in the near future.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"6 1","pages":"vdad171"},"PeriodicalIF":0.0,"publicationDate":"2023-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10907005/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140023843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Growth dynamics of untreated meningiomas.","authors":"Per Sveino Strand, Kathrine Jørgensen Wågø, André Pedersen, Ingerid Reinertsen, Olivia Nälsund, Asgeir Store Jakola, David Bouget, Sayied Abdol Mohieb Hosainey, Lisa Millgård Sagberg, Johanna Vanel, Ole Solheim","doi":"10.1093/noajnl/vdad157","DOIUrl":"10.1093/noajnl/vdad157","url":null,"abstract":"<p><strong>Background: </strong>Knowledge about meningioma growth characteristics is needed for developing biologically rational follow-up routines. In this study of untreated meningiomas followed with repeated magnetic resonance imaging (MRI) scans, we studied growth dynamics and explored potential factors associated with tumor growth.</p><p><strong>Methods: </strong>In a single-center cohort study, we included 235 adult patients with radiologically suspected intracranial meningioma and at least 3 MRI scans during follow-up. Tumors were segmented using an automatic algorithm from contrast-enhanced T1 series, and, if needed, manually corrected. Potential meningioma growth curves were statistically compared: linear, exponential, linear radial, or Gompertzian. Factors associated with growth were explored.</p><p><strong>Results: </strong>In 235 patients, 1394 MRI scans were carried out in the median 5-year observational period. Of the models tested, a Gompertzian growth curve best described growth dynamics of meningiomas on group level. 59% of the tumors grew, 27% remained stable, and 14% shrunk. Only 13 patients (5%) underwent surgery during the observational period and were excluded after surgery. Tumor size at the time of diagnosis, multifocality, and length of follow-up were associated with tumor growth, whereas age, sex, presence of peritumoral edema, and hyperintense T2-signal were not significant factors.</p><p><strong>Conclusions: </strong>Untreated meningiomas follow a Gompertzian growth curve, indicating that increasing and potentially doubling subsequent follow-up intervals between MRIs seems biologically reasonable, instead of fixed time intervals. Tumor size at diagnosis is the strongest predictor of future growth, indicating a potential for longer follow-up intervals for smaller tumors. Although most untreated meningiomas grow, few require surgery.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"6 1","pages":"vdad157"},"PeriodicalIF":0.0,"publicationDate":"2023-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10771275/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139379084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges and limitations of clinical trials in the adolescent and young adult CNS cancer population: A systematic review.","authors":"Emma M Byrne, Maeve Pascoe, Diane Cooper, Terri S Armstrong, Mark R Gilbert","doi":"10.1093/noajnl/vdad159","DOIUrl":"10.1093/noajnl/vdad159","url":null,"abstract":"<p><strong>Background: </strong>The adolescent and young adult (AYA) cancer population, aged 15-39, carries significant morbidity and mortality. Despite growing recognition of unique challenges with this age group, there has been little documentation of unmet needs in their care, trial participation, and quality of life, particularly in those with primary brain tumors.</p><p><strong>Methods: </strong>A systematic literature review of 4 databases was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards. Studies included editorials, reviews, and practice guidelines on the challenges and limitations faced by the AYA population. Papers had to address CNS tumors.</p><p><strong>Results: </strong>Sixty-eight studies met the inclusion criteria. The challenges and limitations in clinical trials in the AYA population were synthesized into 11 categories: molecular heterogeneity, tumor biology, diagnostic delay, access to care, physician factors, patient factors, primary brain tumor (PBT) factors, accrual, limited trials, long term follow up, and trial design. The published papers' recommendations were categorized based on the target of the recommendation: providers, coordination of care, organizations, accrual, and trial design. The AYA cancer population was found to suffer from unique challenges and barriers to care and the construction of trials.</p><p><strong>Conclusions: </strong>The AYA CNS cancer population suffers from unique challenges and barriers to care and construction of trials that make it critical to acknowledge AYAs as a distinct patient population. In addition, AYAs with primary brain tumors are underrecognized and underreported in current literature. More studies in the AYA primary brain tumor patient population are needed to improve their care and participation in trials.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"6 1","pages":"vdad159"},"PeriodicalIF":0.0,"publicationDate":"2023-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10798804/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139514463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to: Impact of extent of resection on outcome from glioblastoma using the RANO resect group classification system: a retrospective, population-based cohort study.","authors":"","doi":"10.1093/noajnl/vdad155","DOIUrl":"https://doi.org/10.1093/noajnl/vdad155","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1093/noajnl/vdad126.].</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"5 1","pages":"vdad155"},"PeriodicalIF":0.0,"publicationDate":"2023-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10708928/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138815990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-derived glioblastoma organoids reflect tumor heterogeneity and treatment sensitivity.","authors":"Maikel Verduin, Linde Hoosemans, Maxime Vanmechelen, Mike van Heumen, Jolanda A F Piepers, Galuh Astuti, Linda Ackermans, Olaf E M G Schijns, Kim R Kampen, Vivianne C G Tjan-Heijnen, Buys A de Barbanson, Alida A Postma, Danielle B P Eekers, Martijn P G Broen, Jan Beckervordersandforth, Katerina Staňková, Frederik de Smet, Jeremy Rich, Christopher G Hubert, Gregory Gimenez, Aniruddha Chatterjee, Ann Hoeben, Marc A Vooijs","doi":"10.1093/noajnl/vdad152","DOIUrl":"10.1093/noajnl/vdad152","url":null,"abstract":"<p><strong>Background: </strong>Treatment resistance and tumor relapse are the primary causes of mortality in glioblastoma (GBM), with intratumoral heterogeneity playing a significant role. Patient-derived cancer organoids have emerged as a promising model capable of recapitulating tumor heterogeneity. Our objective was to develop patient-derived GBM organoids (PGO) to investigate treatment response and resistance.</p><p><strong>Methods: </strong>GBM samples were used to generate PGOs and analyzed using whole-exome sequencing (WES) and single-cell karyotype sequencing. PGOs were subjected to temozolomide (TMZ) to assess viability. Bulk RNA sequencing was performed before and after TMZ.</p><p><strong>Results: </strong>WES analysis on individual PGOs cultured for 3 time points (1-3 months) showed a high inter-organoid correlation and retention of genetic variants (range 92.3%-97.7%). Most variants were retained in the PGO compared to the tumor (range 58%-90%) and exhibited similar copy number variations. Single-cell karyotype sequencing demonstrated preservation of genetic heterogeneity. Single-cell multiplex immunofluorescence showed maintenance of cellular states. TMZ treatment of PGOs showed a differential response, which largely corresponded with <i>MGMT</i> promoter methylation. Differentially expressed genes before and after TMZ revealed an upregulation of the JNK kinase pathway. Notably, the combination treatment of a <i>JNK</i> kinase inhibitor and TMZ demonstrated a synergistic effect.</p><p><strong>Conclusions: </strong>Overall, these findings demonstrate the robustness of PGOs in retaining the genetic and phenotypic heterogeneity in culture and the application of measuring clinically relevant drug responses. These data show that PGOs have the potential to be further developed into avatars for personalized adaptive treatment selection and actionable drug target discovery and as a platform to study GBM biology.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"5 1","pages":"vdad152"},"PeriodicalIF":0.0,"publicationDate":"2023-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10733660/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138833796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic landscape and actionable mutations of brain metastases derived from non-small cell lung cancer: A systematic review.","authors":"Lily J Andrews, Zak A Thornton, Ruqiya Saleh, Sarah Dawson, Susan C Short, Richard Daly, Julian P T Higgins, Philippa Davies, Kathreena M Kurian","doi":"10.1093/noajnl/vdad145","DOIUrl":"10.1093/noajnl/vdad145","url":null,"abstract":"<p><strong>Background: </strong>Brain metastases derived from non-small cell lung cancer (NSCLC) represent a significant clinical problem. We aim to characterize the genomic landscape of brain metastases derived from NSCLC and assess clinical actionability.</p><p><strong>Methods: </strong>We searched Embase, MEDLINE, Web of Science, and BIOSIS from inception to 18/19 May 2022. We extracted information on patient demographics, smoking status, genomic data, matched primary NSCLC, and programmed cell death ligand 1 expression.</p><p><strong>Results: </strong>We found 72 included papers and data on 2346 patients. The most frequently mutated genes from our data were <i>EGFR</i> (<i>n</i> = 559), <i>TP53</i> (<i>n</i> = 331), <i>KRAS</i> (<i>n</i> = 328), <i>CDKN2A</i> (<i>n</i> = 97), and <i>STK11</i> (<i>n</i> = 72). Common missense mutations included <i>EGFR</i> L858R (<i>n</i> = 80) and <i>KRAS</i> G12C (<i>n</i> = 17). Brain metastases of ever versus never smokers had differing missense mutations in <i>TP53</i> and <i>EGFR</i>, except for L858R and T790M in <i>EGFR</i>, which were seen in both subgroups. Of the top 10 frequently mutated genes that had primary NSCLC data, we found 37% of the specific mutations assessed to be discordant between the primary NSCLC and brain metastases.</p><p><strong>Conclusions: </strong>To our knowledge, this is the first systematic review to describe the genomic landscape of brain metastases derived from NSCLC. These results provide a comprehensive outline of frequently mutated genes and missense mutations that could be clinically actionable. These data also provide evidence of differing genomic landscapes between ever versus never smokers and primary NSCLC compared to the BM. This information could have important consequences for the selection and development of targeted drugs for these patients.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"5 1","pages":"vdad145"},"PeriodicalIF":0.0,"publicationDate":"2023-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10734675/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138833795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel program of infiltrative control in astrocytomas: ADAM23 depletion promotes cell invasion by activating γ-Secretase complex","authors":"Elisa Helena Farias Jandrey, Gabriela Filoso Barnabé, Marcos Maldaun, Paula Fontes Asprino, Natália Cristina dos Santos, Lilian Tiemi Inoue, Andrei Rozanski, Pedro Alexandre Favoretto Galante, Suely Kazue Nagahashi Marie, Sueli Mieko Oba-Shinjo, Tiago Góss dos Santos, Roger Chammas, Carmen Lucia Penteado Lancellotti, Frank B Furnari, Anamaria Aranha Camargo, Érico Tosoni Costa","doi":"10.1093/noajnl/vdad147","DOIUrl":"https://doi.org/10.1093/noajnl/vdad147","url":null,"abstract":"Abstract Background Infiltration is a life-threatening growth pattern in malignant astrocytomas and a significant cause of therapy resistance. It results in the tumor cell spreading deeply into the surrounding brain tissue, fostering tumor recurrence and making complete surgical resection impossible. We need to thoroughly understand the mechanisms underlying diffuse infiltration to develop effective therapies. Methods We integrated vitro and in vivo functional assays, RNA sequencing, clinical and expression information from public datasets to investigate the role of ADAM23 expression coupling astrocytoma’s growth and motility. Results ADAM23 downregulation resulted in increased infiltration, reduced tumor growth and improved overall survival in astrocytomas. Additionally, we show that ADAM23 deficiency induces γ-secretase (GS) complex activity, contributing to the production and deposition of the Amyloid-β and release of NICD. Finally, GS ablation in ADAM23-low astrocytomas induced a significant inhibitory effect on the invasive programs. Conclusions Our findings reveal a role for ADAM23 in regulating the balance between cell proliferation and invasiveness in astrocytoma cells, proposing GS inhibition as a therapeutic option in ADAM23 low-expressing astrocytomas.","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"116 16","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134957465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}